Germany's Merck has announced the acquisition of Bio-Techne for $11 billion, a move aimed at strengthening its life sciences portfolio.
Bio-Techne is known for its expertise in biotechnology and life sciences tools, which aligns with Merck's strategic objectives.
This deal reflects Merck's commitment to expanding its capabilities within the life sciences industry, although the long-term impacts remain to be seen.